IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

Résumé détaillé

Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP,…

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumor suppressor function in cancer. CDKN2A-deficiency occurs in approximately 10-15% of all solid tumors, including ~70% of pancreatic ductal adenocarcinoma (PDAC), and is typically co-deleted in methylthioadenosine phosphorylase (MTAP)-deficient cancers given their proximity on chromosome 9p21.

"We are excited to announce the nomination of IDE101 as our next development candidate in our precision medicine pipeline. IDE101 is a novel, first-in-class molecule that targets the key drivers of tumorigenesis resulting from CDKN2A-deficiency. We plan to focus development of IDE101 in tumors with a high frequency of CDKN2A-deficiency, including as a monotherapy agent and in combination with RAS inhibitors for pancreatic cancer and in combination with IDE892, our proprietary PRMT5 inhibitor, in MTAP-deleted solid tumors.

IDE101 was discovered through IDEAYA's iterative physics-based ligand design and optimization platform and is a highly potent and selective dual CDK inhibitor with first-in-class potential and favorable drug-like properties. IND-enabling studies for IDE101 are ongoing to support an Investigational New Drug (IND) filing to the U.S. Food and Drug Administration (FDA) in the first half of 2027, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.